FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947185312> ?p ?o ?g. }

• W2947185312 abstract "e12554 Background: Triple-negative breast cancer is a biologically aggressive disease that accounts for 15% of all breast cancers, of which around 4-5% are metastatic (mTNBC) at diagnosis. Notably, there is no standard of care for mTNBC in the first line (1L) setting. This, in addition to higher relapse rates and poor long-term survival, warrants evaluation of real-world treatment patterns, especially in the 1L setting, to better inform on clinical outcomes. Methods: This observational, retrospective, chart review study included a cohort of twenty-six mTNBC patients from six different sites Australia, who commenced 1L treatment between July 1, 2012 and June 30, 2015. Medical records of eligible patients were abstracted using electronic case report forms after gaining relevant ethics approvals. Data on treatment patterns and clinical outcomes in the 1L setting were then collected from the index date until the end of data abstraction or death. The index date is defined as the date of initiation of 1L systemic therapy for mTNBC. Results: In the 1L setting, patients that received combination (52%) chemotherapy was slightly higher than single-agent (48%) chemotherapy. The commonest combination used was Carboplatin-Gemcitabine (12%), and the most common monotherapy was Nab-Paclitaxel (24%). The overall response rate and disease control rate were estimated to be 32% and 60% in the 1L setting. The median duration of treatment and the median time to next line of therapy were calculated to be 98 days and 12.45 (95% CI 2.79, 20.30) months respectively. Importantly, the median progression free survival (sensitivity analysis) and the median overall survival were estimated to be 3.17 (95% CI 1.91, 5.09) and 10.41 (95% CI 5.36, 16.53) months respectively. Conclusions: Chemotherapy is currently the mainstay of treatment for mTNBC. However, disease progression and chemo-related toxicities warrant stratified use of more efficacious and tolerable treatment options, especially in the 1L setting. Results from this study could be useful in comparing the efficacy and cost effectiveness of these emerging targeted and immuno-therapies outside the clinical trial setting." @default.
• W2947185312 created "2019-06-07" @default.
• W2947185312 creator A5004640413 @default.
• W2947185312 creator A5008184071 @default.
• W2947185312 creator A5019911480 @default.
• W2947185312 creator A5025604398 @default.
• W2947185312 creator A5031052411 @default.
• W2947185312 creator A5032945961 @default.
• W2947185312 creator A5059454613 @default.
• W2947185312 creator A5065756310 @default.
• W2947185312 creator A5075510355 @default.
• W2947185312 creator A5076055015 @default.
• W2947185312 creator A5079207887 @default.
• W2947185312 date "2019-05-20" @default.
• W2947185312 modified "2023-09-27" @default.
• W2947185312 title "Learning from every patient: Real-world clinical outcomes of patients with metastatic triple-negative breast cancer treated in the community oncology setting." @default.
• W2947185312 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e12554" @default.
• W2947185312 hasPublicationYear "2019" @default.
• W2947185312 type Work @default.
• W2947185312 sameAs 2947185312 @default.
• W2947185312 citedByCount "0" @default.
• W2947185312 crossrefType "journal-article" @default.
• W2947185312 hasAuthorship W2947185312A5004640413 @default.
• W2947185312 hasAuthorship W2947185312A5008184071 @default.
• W2947185312 hasAuthorship W2947185312A5019911480 @default.
• W2947185312 hasAuthorship W2947185312A5025604398 @default.
• W2947185312 hasAuthorship W2947185312A5031052411 @default.
• W2947185312 hasAuthorship W2947185312A5032945961 @default.
• W2947185312 hasAuthorship W2947185312A5059454613 @default.
• W2947185312 hasAuthorship W2947185312A5065756310 @default.
• W2947185312 hasAuthorship W2947185312A5075510355 @default.
• W2947185312 hasAuthorship W2947185312A5076055015 @default.
• W2947185312 hasAuthorship W2947185312A5079207887 @default.
• W2947185312 hasConcept C121608353 @default.
• W2947185312 hasConcept C126322002 @default.
• W2947185312 hasConcept C143998085 @default.
• W2947185312 hasConcept C2775930923 @default.
• W2947185312 hasConcept C2776598537 @default.
• W2947185312 hasConcept C2780110267 @default.
• W2947185312 hasConcept C2992734768 @default.
• W2947185312 hasConcept C530470458 @default.
• W2947185312 hasConcept C71924100 @default.
• W2947185312 hasConceptScore W2947185312C121608353 @default.
• W2947185312 hasConceptScore W2947185312C126322002 @default.
• W2947185312 hasConceptScore W2947185312C143998085 @default.
• W2947185312 hasConceptScore W2947185312C2775930923 @default.
• W2947185312 hasConceptScore W2947185312C2776598537 @default.
• W2947185312 hasConceptScore W2947185312C2780110267 @default.
• W2947185312 hasConceptScore W2947185312C2992734768 @default.
• W2947185312 hasConceptScore W2947185312C530470458 @default.
• W2947185312 hasConceptScore W2947185312C71924100 @default.
• W2947185312 hasLocation W29471853121 @default.
• W2947185312 hasOpenAccess W2947185312 @default.
• W2947185312 hasPrimaryLocation W29471853121 @default.
• W2947185312 hasRelatedWork W2017194396 @default.
• W2947185312 hasRelatedWork W2027008303 @default.
• W2947185312 hasRelatedWork W2084058881 @default.
• W2947185312 hasRelatedWork W2340502289 @default.
• W2947185312 hasRelatedWork W2353696416 @default.
• W2947185312 hasRelatedWork W2560276263 @default.
• W2947185312 hasRelatedWork W2560612304 @default.
• W2947185312 hasRelatedWork W2586789354 @default.
• W2947185312 hasRelatedWork W2593418965 @default.
• W2947185312 hasRelatedWork W2596678332 @default.
• W2947185312 hasRelatedWork W2612328330 @default.
• W2947185312 hasRelatedWork W2678395490 @default.
• W2947185312 hasRelatedWork W2763156313 @default.
• W2947185312 hasRelatedWork W2936394447 @default.
• W2947185312 hasRelatedWork W2954662492 @default.
• W2947185312 hasRelatedWork W2978752316 @default.
• W2947185312 hasRelatedWork W3030206129 @default.
• W2947185312 hasRelatedWork W304973347 @default.
• W2947185312 hasRelatedWork W3202221918 @default.
• W2947185312 hasRelatedWork W750091570 @default.
• W2947185312 isParatext "false" @default.
• W2947185312 isRetracted "false" @default.
• W2947185312 magId "2947185312" @default.
• W2947185312 workType "article" @default.